As a seasoned patent professional, you are confident in your strategy. But more and more often, your clients are demanding proof of your data-driven decision-making.  

We are entering a time of year where, as a prosecution manager, paralegal, assistant, or another member of the support staff, you're probably facing a packed calendar and your to-do list is anything but to-done.

Maybe you were taken in by an ad for workflow automation that could help your overworked support staff, maybe you hit the search bar looking for a way to reduce your IDS workload, or maybe you were tired of the other firms standing out to corporate clients with their use of data analytics.

Whatever the reason, you need to know that investing in legal tech is going to be worth the cost to your firm. So you negotiated a free trial, and you’ve got seven or 14, or 30 days to make sure this product will fulfill your needs.

Juristat continues to build products that speed up and simplify your patent prosecution.

Juristat is moving beyond patent prosecution strategy, creating products and features that simplify patent litigation and workflow automation. See what’s new, including our powerful PTAB Expert Search, comprehensive office action response tracking, and improved printing capabilities.

To succeed in any industry, a certain amount of foresight and planning is key. For patent attorneys, identifying and taking action on high-cost prosecution can lessen the usual timeline and save money in the long term.

Patent prosecution is expensive and complex. And often, each individual practitioner has their own unique approach to reach that all-important NOA. But inconsistent practices and reliance solely on past experience can lead to inflated costs.

Much has been made about the economic effects of the COVID-19 pandemic. While it is clear that the pandemic and its associated lockdowns have resulted in a sharp economic contraction, it is unclear what effect—if any—it will have on the USPTO in terms of patent filing and other patent prosecution-related activity.

In early June, AstraZeneca approached rival drugmaker Gilead Sciences to discuss a potential merger. Though some doubt the feasibility of such a deal, this would be the biggest healthcare merger on record.

Prompted by the CARES Act, the USPTO announced extensions to the time allowed to file certain patent-related documents and to pay certain required fees. Legal teams can use patent analytics tools like Juristat to quickly identify which applications qualify.